1. Background {#sec0005}
=============

Reflecting the success of vaccination campaigns, the global prevalence of chronic Hepatitis B Virus (HBV) infection has fallen since 1990; however, the absolute number of cases has continued to rise [@bib0005], highlighting the critical need for ongoing efforts to reduce transmission. The World Health Organisation Expanded Programme on Immunisation (EPI) recommends that all infants in settings where HBV prevalence is ≥2% should receive three or four doses of HBV vaccine, with the first dose in the first day of life [@bib0010].

HBV vaccination has been implemented in South Africa since 1995, but the locally recommended schedule is to postpone the first dose until age six weeks [@bib0015], [@bib0020]. Recently, HBV immunisation has been incorporated into a hexavalent vaccine together with diphtheria, tetanus, pertussis, inactivated poliomyelitis and *Haemophilus influenzae* type b (Hexaxim, Sanofi-Pasteur). It is recognized that children with HIV infection may not mount adequate vaccine-mediated immunity [@bib0025], potentially making this a vulnerable group.

In a recent study to ascertain the epidemiology of HBV in South African adults, we identified HBsAg in 8.3% of HIV-negative, and 9.7% of HIV-positive adults [@bib0030]. Published around the same time, a study from the Western Cape reports 0.4% prevalence of HBV in HIV exposed-uninfected (HEU) infants, all of whom were HBV-immunised according to local policy [@bib0020]. Together, these data highlight that chronic HBV is a persistent problem in South African adults, irrespective of HIV status, and that infants remain vulnerable to vertical acquisition of HBV infection before receiving their first dose of vaccine. In this setting, the high seroprevalence of HIV infection puts infants and young children at increased risk of co-infection and of complications of chronic HBV infection [@bib0020], [@bib0035]. Our recent study found HBsAg in 11% of HIV-positive mothers of children attending outpatient clinics in Kimberley [@bib0030], but HBV-screening has not been routinely incorporated into clinical care.

2. Objectives {#sec0010}
=============

We set out to investigate whether there is evidence of ongoing HBV transmission in our HIV-positive paediatric cohort in Kimberley, South Africa, to ascertain the feasibility of incorporating this into routine clinical care, and to characterise the cases of infection identified. This study aims to inform ongoing efforts in HBV screening, treatment and prevention.

3. Study design {#sec0015}
===============

We implemented screening for HBsAg in HIV-infected children (age \<17 years) attending out-patient clinics at Kimberley Hospital in South African's Northern Cape, during a fifteen-month period commencing March 2015. HBV screening was introduced as part of routine clinical care in keeping with WHO and CDC recommendations [@bib0040], [@bib0045].

Among children who tested HBsAg positive, we obtained written informed consent for study enrollment from the child (according to age/ability) and their parent/guardian. This study was approved under the terms of the Ethics Committee of the Faculty of Health Science, University of Free State, Bloemfontein, South Africa (ref. ETOVS Nr 08/09).

We recorded HBV vaccination history for children who attended with their hand-held records (Road to Health Book). HBsAg testing was performed by the clinical laboratory at Kimberley Hospital, using the Magnetic parcel chemiluminometric immunoassay (MPCI; Advia Centaur platform), re-testing samples from an alternative time-point to confirm, where possible. For children testing HBsAg positive, we stored serum at −80 °C and shipped samples to the Oxford University Hospitals microbiology laboratory. We repeated testing for HBsAg, and additionally performed assays for HBeAg, HBeAb, HBc IgM, HBsAb (all on Architect i2000), and HBV DNA quantification (Cobas ampliprep).

4. Results {#sec0020}
==========

Over a 15-month period, we screened 625 HIV-infected children and adolescents for HBV infection (331 male, 294 female; median age 10.8 years, IQR 6.6--13.8 years). We identified five (0.8%) who were positive for HBsAg ([Table 1](#tbl0005){ref-type="table"}) including a sibling pair (KHep004 and KHep005).

A further two children who initially tested HBsAg-positive (KHep001 and KHep003) were negative on repeat testing, and also negative for anti-HBc and for HBV DNA, suggesting that the initial assay had yielded a false positive result. KHep006 followed the same initial pattern (initially HBsAg positive, but negative on follow-up) but had detectable HBV DNA, supporting the presence of true infection. For KHep007, our confirmation HBsAg test was done on a sample collected at an earlier timepoint (based on sample availability). This child tested negative in 2014, but positive in 2016, suggesting either fluctuations in low level HBsAg, or a new infection acquired subsequent to 2014. These cases collectively illustrate the importance of following-up positive screening results with a confirmation HBsAg test and PCR for HBV DNA.

Only 45 children in this cohort (7%) attended clinic with their vaccine records (Road to Health Book). Not surprisingly, this group was significantly younger than the rest of the cohort, as parents/guardians of infants and younger children are more likely to attend with vaccine records (median age of children with records 3.9 years, compared to 11.3 years in those without; p \< 0.0001). Of these 44/45 had received all three HBV vaccine doses, and the remaining child had received two doses. One of these 45 was KHep003, who initially tested HBsAg positive, but was negative for HBsAg and HBV DNA on follow-up.

One of the five children with detectable HBV DNA had a positive anti-HBs result (KHep006), suggesting prior immunization. This child seroconverted from HBsAg-positive to HBsAg-negative, and had only low-level viraemia. We did not identify any child positive for anti-HBc IgM, suggesting that none of the five cases was acutely infected. We detected HBeAg in 3/5 HBsAg-positive children; no case had detectable anti-HBe ([Table 1](#tbl0005){ref-type="table"}).

Current South African ART guidelines recommend children are treated with ABC + 3TC + either rLPV or EFV, but make no specific recommendations for therapy in the context of HBV co-infection [@bib0050]. At the time of screening positive for HBsAg, all five of our HBV-infected children were on ART regimens incorporating HBV-active agents (3TC or TDF). In the case of KHep002, the high HBV DNA level despite 3TC-containing therapy prompted a therapy switch. Efforts are currently underway to identify and screen household contacts with the view to treating infection and vaccinating susceptible individuals.

5. Discussion {#sec0025}
=============

This study demonstrates that HBV screening is feasible as part of routine clinical care for children and adolescents with HIV attending outpatient clinics in South Africa. We now propose to continue this screening as part of routine state-funded care.

Identifying HBV cases allows optimization of antiviral treatment regimens; the case of KHep002 highlights how diagnosing and monitoring HBV infection can have important bearing on the choice of ART regimen. The identification of an infected sibling pair in this cohort demonstrates the need for particular vigilance around the risk of clustering in families, underlining the importance of preventive measures in tandem with screening.

Both our data-set and another recent study [@bib0025] demonstrate the success of the existing vaccine campaign in reducing paediatric HBV prevalence. However, there is undoubtedly a need for ongoing vigilance and efforts to reduce transmission still further. Together with the recent results from the Western Cape [@bib0020], these studies suggest that strategies to prevent mother to child HBV transmission have been successful, but need to remain an important focus. Furthermore, there are ongoing challenges; HBV immunisation is not routinely available for adults in the public sector (though should be available for those at risk), and availability of the new hexavalent vaccine has been problematic.

Routine maternal screening for HBV during pregnancy would yield benefits for both mother and child, including clinical assessment and appropriate treatment for adult infection, and implementation of measures to reduce both vertical and within-household transmission [@bib0055]. Ongoing evaluation of the risks and benefits of the timing of the first HBV vaccine dose is required. HBV immunisation at birth would further reduce perinatal transmission events, and could be given as a monovalent vaccine, with the hexavalent vaccine following at six weeks to boost antibody responses.

The data presented here may under-represent the true prevalence of HBV infection, by missing cases with low level HBs-antigenaemia or in which mutations in HBsAg render the surface antigen assay negative [@bib0060]. In future studies, screening using HBV DNA as a more sensitive measure could be considered. However, this is not routinely available and is more expensive, and is therefore currently not feasible in South Africa.

We have been unable to make a robust assessment of the specific details of vaccination history within this cohort, as only 7% of the cohort had available vaccination records. This small subgroup cannot be deemed representative of the wider population (indeed, it would be reasonable to hypothesise that families most likely to access all three vaccine doses might also be those who are also most likely to bring their vaccine records to clinic).

Future studies are therefore required to quantify the titres of vaccine-mediated HBsAb present in this population. Nevertheless, a prevalence of HBV infection of \<1% in children compared to 11% in the adult population [@bib0030] suggests a substantial reduction in transmission, much of which is likely to be attributable to successful vaccination. While celebrating the impact of campaigns to reduce HBV infection, we should maintain a high level of scrutiny to detect cases and continue intensive efforts to reduce transmission.
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Characteristics of five HIV-infected children testing positive for HBsAg in Kimberley, South Africa.

Table 1

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID[a](#tblfn0005){ref-type="table-fn"}                                              KHep002 (ART2156)               KHep004[b](#tblfn0010){ref-type="table-fn"}\   KHep005[b](#tblfn0010){ref-type="table-fn"} (ART2096)   KHep006 (ART1585)               KHep007\
                                                                                                                            (ART1917)                                                                                                                              (ART1638)
  ----------------------------------------------------------------------------------------- ------------------------------- ---------------------------------------------- ------------------------------------------------------- ------------------------------- -----------------------------------------------------------------
  Sex                                                                                       F                               M                                              F                                                       M                               F

  Age (years) at time of HBV screening                                                      6.8                             6.4                                            15.6                                                    5.6                             5.3

  Number of doses of HBV vaccine                                                            3                               Unknown                                        Unknown                                                 Unknown                         Unknown

  HBsAg test date and result (MPCI[c](#tblfn0015){ref-type="table-fn"} Kimberley)           Oct 2015; Detected              Apr 2015; Detected                             Jul 2015;\                                              Jul 2015;\                      Jan 2016;\
                                                                                                                                                                           Detected                                                Detected                        Detected

  Repeat HBsAg test date and result (MPCI[b](#tblfn0010){ref-type="table-fn"}, Kimberley)   Nov 2015; Detected              Nov 2015; Detected                             Nov 2015; Detected                                      Feb 2016;\                      Not done
                                                                                                                                                                                                                                   Detected                        

  Date of sample used for confirmation HBsAg test; result (Architect, Oxford)               Nov 2015; Detected              Jan 2014; Detected                             Nov 2015; Detected                                      Feb 2016;\                      Sept 2014;\
                                                                                                                                                                                                                                   Not detected                    Not detected

  Hepatic transaminase levels (ALT, AST)                                                    Within normal reference range   Within normal reference range                  Within normal reference range                           Within normal reference range   Within normal reference range

  Date and result of most recent HIV VL (RNA copies/ml)                                     Apr 2015;\                      Apr 2015; \<40                                 01/08/2013; 196,111                                     05/01/2014;\                    01/01/2015; \<150
                                                                                            10,931                                                                                                                                 25                              

  Date and result of most recent CD4+ T cell count (CD4%)                                   Apr 2015;\                      Apr 2015;\                                     Feb 2016;\                                              Sept 2015;\                     Jan 2015;\
                                                                                            566 (26%)                       1500 (38.5%)                                   1883 (40.5%)                                            1135 (31%)                      2012 (37.3%)

  ART[d](#tblfn0020){ref-type="table-fn"}: start date and regimen                           Jun 2014; ABC/3TC/\             Oct 2012; ABC/3TC/EFV                          Jan 2014; EFV/FTC/TDF                                   Jan 2014\                       Mar 2011;\
                                                                                            EFV\                                                                                                                                   ABC/3TC/rLPV                    ABC/3TC/rLPV\
                                                                                            In 2016,\                                                                                                                                                              Since 2014, taking 3TC only[e](#tblfn0025){ref-type="table-fn"}
                                                                                            switched to TDF/FTC/rLPV                                                                                                                                               

  HBV DNA (iu/ml)                                                                           36,830,065                      136,875                                        110                                                     260                             167

  HBeAg[f](#tblfn0030){ref-type="table-fn"}                                                 Detected                        Detected                                       Detected                                                Not detected                    Not detected

  Anti-HBe[g](#tblfn0035){ref-type="table-fn"}                                              Not detected                    Not detected                                   Not detected                                            Not detected                    Not detected

  HBsAb[h](#tblfn0040){ref-type="table-fn"}\                                                Not detected                    Not detected                                   Not detected                                            Detected\                       Not detected
  (iU/L)                                                                                                                                                                                                                           (212.2)                         

  Anti-Hbc IgM[i](#tblfn0045){ref-type="table-fn"}                                          Not detected                    Not detected                                   Not detected                                            Not detected                    Not detected

  Total AntiHBc[j](#tblfn0050){ref-type="table-fn"}                                         Not detected                    Not detected                                   Not detected                                            Not detected                    Not detected
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Each child testing positive for HBsAg was assigned a new number with the prefix K-Hep (Kimberley Hepatitis). In addition, these children each have an ART (Anti-Retroviral Therapy) study number which we have retained to ensure we can continue to identify these children for clinical follow-up, and in order to permit cross-reference between studies.

KHep004 and KHep005 are a sibling pair (same mother; different fathers; mother is deceased).

MPCI -- Magnetic Parcel Chemiluminometric Immunoassay.

ART -- antiretroviral therapy; abbreviations for drugs are as follows: ABC = abacavir; 3TC = lamivudine; rLPV = lopinavir with ritonavir boost (children on rLPV are taking combination in the form of Kaletra); EFV = efavirenz.

KHep007 is on 3TC only at present due to difficulties with drug adherence, with a plan in place to continue close surveillance and ultimately restart triple therapy, potentially comprising FTC/TDF/DTG.

HBeAg -- Hepatitis B e-Antigen.

Anti-HBe -- Antibody to Hepatitis B e-Antigen.

HBsAb -- Hepatitis B surface antibody (vaccine mediated).

Anti-Hbc IgM -- IgM antibody to Hepatitis B core protein.

Total Anti-HBc -- Total antibody to Hepatitis B core protein.
